Combination Therapy for Metastatic Melanoma

Overview

This activity is designed to inform physicians about the current and emerging treatment landscape in chronic lymphocytic leukemia (CLL) and factors that influence the sequencing of CLL therapies.

Instructions For This Activity & Receiving Credit

Read the article in its entirety.
Use the QR code or type into your Web browser to access the posttest.
Complete and pass the posttest with a score of 70% or higher.
Complete the evaluation and request for credit.

Target Audience

This activity is directed toward medical oncologists, primary care physicians, nurses, and nurse practitioners who treat and/or manage patients with hematologic malignancies. Surgical oncologists, radiation oncologists, pathologists, internists, fellows, physician assistants, and other healthcare providers with an interest in the current topic are also invited to participate.

Learning Objectives

After participating in this CME activity, learners should be better prepared to:

Identify the factors that guide individualized treatment decision making in patients with newly diagnosed and relapsed/refractory CLL
Summarize key clinical trial findings demonstrating the safety and efficacy of recently approved CLL therapies
Utilize evidence-based data to appropriately implement new CLL therapies into clinical practice
Recognize the advantages and limitations of allogeneic hematopoietic stem cell transplantation in patients with CLL
Discuss novel agents that are currently under investigation as monotherapy or in combination with other agents in the treatment of patients with CLL

The American Journal of Hematology/ Oncology^® Editorial Board

Debu Tripathy, MD
Professor and Chairman
Department of Breast Medical Oncology
The University of Texas MD Anderson Cancer Center
Houston, TX
Disclosure: Grant/research support from Genentech/Roche, Pfizer, Puma Biotechnology Inc, and Novartis (clinical trial support contracted to the University of Southern California and MD Anderson Cancer Center); consultant for Eisai, OncoPlex Diagnostics, Merck, and Novartis.

Faculty

Susan M. O’Brien MD
Associate Director for Clinical Science,
Chao Family Comprehensive Cancer Center
Medical Director,
Sue and Ralph Stern Center for Cancer Clinical Trials and Research
UC Irvine Health
Disclosure: Grant/Research Support - Acerta, TG Therapeutics, Regeneron, Gilead, Pharmacylics, ProNAi Consultant - Amgen, Celgene, GSK, Janssen

Staff/Planner Disclosures and Conflict of Interest Resolution

The staff of Physicians' Education Resource^®, LLC, (PER^®) and the editorial staff of The American Journal of Hematology/Oncology^® have no relevant financial relationships with commercial interests to disclose.

It is the policy of PER^® to ensure fair balance, independence, objectivity, and scientific objectivity in all of our CME/CE activities. In accordance with ACCME guidelines, PER^® requires everyone who is in a position to control the content of an educational activity, including spouses/partners, to disclose all relevant financial relationships with any commercial interest to participants as part of the activity planning process. PER^® has implemented mechanisms to identify and resolve all conflicts of interest prior to release of this activity.

Accreditation/Credit Designation

Physicians' Education Resource^®, LLC, is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Physicians' Education Resource^®, LLC, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit ™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians’ Education Resource^®, LLC is approved by the California Board of Registered Nursing, Provider #16669 for 1.0 Contact Hour.

This activity is funded by PER^®.

Off-Label Disclosure and Disclaimer

This continuing medical and nursing education activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME activity is for CME purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options for a specific patient's medical condition.

Disclaimer

The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of Physicians' Education Resource^®,LLC

2 Clarke Drive
Suite 100
Cranbury, NJ 08512
Phone: (888) 949-0045
E-mail: [email protected]